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Abstract
Background: The objective of this study was to assess the level of knowledge of cervical cancer among Bangladeshi
women and to assess their willingness to receive the human papillomavirus (HPV) vaccine.
Methods: A population-based, cross-sectional survey was conducted from July to December 2011 in one urban and
one rural area of Bangladesh. A total of 2037 ever-married women, aged 14 to 64 years, were interviewed using a
structured questionnaire. Data on socio-demographic characteristics and knowledge of cervical cancer were collected.
Willingness to receive the HPV vaccine was assessed. Univariate analyses were completed using quantitative data
collected. Multivariable logistic regression models were developed to identify factors associated with having heard of
cervical cancer and the HPV vaccine.
Results: The majority of study participants reported to have heard of cervical cancer (urban: 89.7%, rural 93.4%; P = 0.
003). The odds of having heard of cervical cancer were significantly higher in urban women aged 35–44 years (aOR: 2.
92 (1.34–6.33) and rural women aged 25–34 years (aOR: 2.90 (1.24–6.73) compared to those aged less than 24 years.
Very few women reported to have detailed knowledge on risk factors (urban:9.1%, rural: 8.8%) and prevention (urban:
6.4%, rural: 4.4%) of cervical cancer. In our sample, one in five urban women and one in twenty rural women heard
about a vaccine that can prevent cervical cancer. Among urban women, secondary education or higher (aOR: 3.48,
95% CI: 1.67–7.25), age of 20 years and above at marriage (aOR: 2.83, 95% CI: 1.61–5.00), and high socioeconomic status
(aOR: 2.25, 95% CI: 1.28–3.95) were factors associated with having heard of the HPV vaccine. Willingness to receive the
HPV vaccine among study participants either for themselves (urban: 93.9%, rural: 99.4%) or for their daughters (urban:
91.8%, rural: 99.2%) was high.
Conclusions: Detailed knowledge of cervical cancer among Bangladeshi women was found to be poor. Education on
cervical cancer must include information on symptoms, risk factors, and preventive methods. Despite poor knowledge,
the study population was willing to receive the HPV vaccine.
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Background
Globally, cervical cancer is the fourth most common
cancer among women, with an estimated 528,000 new
cases in 2012 [1]. A large majority of the global burden
of cervical cancer occurs in less developed regions,
where almost nine in ten (87%) deaths are due to cer-
vical cancer [1]. Such disproportionately high mortality
rates have been attributed to several factors, including
lack of availability of organized and high quality cervical
cancer screening and treatment programs, lack of know-
ledge of cervical cancer, attitudinal barriers, and poor
health systems infrastructure [2–5]. In Bangladesh, cer-
vical cancer is the second most common cancer amongst
women with an estimated 11,956 incident cases and
6582 deaths in 2012 [6].
Human papillomavirus (HPV) is the necessary cause
of cervical cancer [7]. Persistent infection of approxi-
mately 15 high-risk HPV genotypes cause almost all
cases of cervical cancer and its immediate precursor le-
sions [8]. Of these genotypes, HPV-16 and HPV-18 ac-
count for about 70% of global cervical cancer cases, with
HPV-16 causing about 55–60% and HPV-18 about 10–
15% [9]. Similarly, according to our previously published
findings, HPV-16 is the most common high-risk HPV
genotype detected in Bangladeshi women [10]. This con-
sistent global discovery has resulted in the major devel-
opment of primary prevention of cervical cancer
through HPV vaccination of young adolescents [11].
Currently, there are three types of HPV vaccines avail-
able in the global market: nonavalent vaccine “Gardasil
– 9™,” quadrivalent “Gardasil™” and bivalent “Cervarix™.”
The HPV vaccine has demonstrated high degrees of
efficacy with maximum clinical effectiveness and cost-
effectiveness in the target population of young adoles-
cents, who are less likely to have been previously
exposed to high-risk HPV genotypes [12, 13]. As these
vaccines are highly effective before exposure to HPV,
current guidelines prioritize adolescent girls as the pri-
mary target group for HPV vaccination [14].
While the vaccine has been shown to be efficacious,
high vaccine uptake is essential for successful HPV vac-
cine program implementation [15]. Several factors have
been attributed to high vaccine uptake among women,
including knowledge of cervical cancer and the HPV
vaccine, and its associated benefits [15], specifically in
the United States (U.S.) and Australia. Additional studies
conducted in the U.S. have shown that caregivers of vac-
cinated children are more likely to be knowledgeable of
the HPV vaccine than caregivers of non-vaccinated chil-
dren [16, 17]. However, research conducted in develop-
ing countries, including Kenya and Nepal, have shown
high HPV vaccine acceptability and willingness to re-
ceive the vaccine among women, despite low to moder-
ate levels of knowledge of cervical cancer and the HPV
vaccine [18, 19]. Country-level data on knowledge of
cervical cancer and attitudes towards the HPV vaccine
among Bangladeshi women are imperative for resource
allocation of cervical cancer primary prevention pro-
grams and to identify target groups for future educa-
tional programs. Data are particularly necessary as the
HPV vaccine has been recently introduced in 2016 for
the first time in Bangladesh by the Ministry of Health,
with support from the Global Alliance for Vaccines and
Immunizations (GAVI) [20].
Among Bangladeshi women, one previous report has
documented high (81%) awareness of cervical cancer,
however, the majority (74%) of these data were collected
from women residing in rural areas and limited to
women above the age of 30 years [21]. Additionally, in-
depth knowledge on cervical cancer, such as risk factors
or symptoms, was not assessed. Data on knowledge of
cervical cancer among a more representative sample, in-
cluding those residing in urban areas and younger popu-
lations, are needed. Additionally, data on knowledge of
HPV and the HPV vaccine among Bangladeshi women
are currently not available in the literature. Therefore,
the objective of this study was to assess women’s know-
ledge of cervical cancer and willingness to receive the
HPV vaccine among women residing in both rural and
urban areas in Bangladesh. Additionally, factors associ-
ated with having heard of cervical cancer and the HPV
vaccine were identified by urban and rural area of resi-
dence among this population. We hypothesized that
knowledge of cervical cancer will be low and willingness
to receive the HPV vaccine will be high, similar to other
developing countries in the region.
Methods
Study population
Data for this study were collected during the baseline as-
sessment of a population-based longitudinal cohort
study developed to estimate the overall burden of HPV
infection and risk factors associated with persistent
infection among females in Bangladesh. This cross-
sectional survey was conducted between July and De-
cember of 2011 in one rural and urban area of
Bangladesh. The urban area was located in Dhaka, the
capital of Bangladesh. Since 2010, the International
Centre for Diarrhoeal Disease Research, Bangladesh
(icddr,b), an international research organization, has
maintained a surveillance site for on-going research pro-
jects in Dhaka in one specific administrative ward (smal-
lest administrative urban geographic unit), which covers
a population of approximately 27,000. To construct the
sampling frame for the urban site, the administrative
ward was divided into nine clusters, of which three were
selected for this study. The rural area was located in
Mirzapur, a sub-district of Tangail district. In Tangail,
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icddr,b has organized a demographic surveillance site
since 2007. This surveillance site includes a population
of approximately 240,000 and consists of eight unions
(smallest administrative rural geographic unit). Of these
eight unions, two were purposely selected and included
in the sampling frame for the rural site. Systematic ran-
dom sampling technique was used to select women in
both areas.
Women who were ever-married, aged 14–64 years and
residing in the study areas were invited to the study
clinic for further assessment by the study physician.
Women who were pregnant, post-partum, or with a his-
tory of hysterectomy, cervical cancer, uterine prolapse or
with major psychological/psychiatric problems were ex-
cluded after history taking and/or clinical examination
by the study physician. Pregnant women and women
who were post-partum were excluded as cervical sam-
pling implements may cause bleeding and interfere with
the HPV test results. Further details regarding sampling
methods, data collection, HPV testing and survey imple-
mentation methods have been previously published [10].
Survey instrument
Upon providing consent, women were interviewed using
a structured and close-ended questionnaire, which col-
lected demographic information, reproductive history,
lifestyle factors such as condom and tobacco use, and
knowledge of cervical cancer and attitudes towards the
HPV vaccine. In order to assess knowledge of cervical
cancer, participants were asked if they had “ever heard
of a cancer called cervical cancer?” If participants
responded, “Yes,” then a series of questions to assess
women’s knowledge related to the disease and attitudes
towards the HPV vaccination were asked, however, if a
participant responded “No” then knowledge of cervical
cancer and attitudes towards the HPV vaccine was not
further assessed.
In order to assess knowledge, the following questions
were asked: (1) “From where did you hear about cervical
cancer?”; (2) “Do you know how a woman can get this
cancer?”; (3) “If yes, how can a woman get this cancer?”;
(4) “Do you think cervical cancer can be prevented?”;
and (5) “If yes, how can it be prevented?” Possible re-
sponses to all knowledge questions were defined in the
questionnaire, including an “Other” option. Participants
were able to provide a free response if they chose
“Other.” Responses to “Other” were recoded and in-
cluded in the analysis. Participants were able to provide
more than one response for each question.
Next, participants were asked a series of questions to
assess their attitudes towards the HPV vaccination. If a
participant had previously indicated they had never
heard of cervical cancer, then these questions were
skipped. Questions related to attitudes towards the HPV
vaccination included, (1) “Have you heard of a vaccine
to prevent cervical cancer?”; (2) “Would you support a
measure to prevent cervical cancer?”; (3) “If there was
such a vaccine available, would you take the vaccine to
prevent cervical cancer?”; (4) “Would you be willing to
give your daughter such a vaccine?”; and (5) “Would you
be willing to recommend the vaccine to others?” Partici-
pants were able to answers these questions with either
“Yes,” “No” or “Not Sure/Don’t Know.”
Sample size
The sample size necessary to carry out this study was
calculated using the parent study’s objective to assess the
prevalence of HPV in the Bangladeshi population. Prior
to our study, the prevalence of HPV in Bangladesh was
unknown. Based on estimates of HPV prevalence from
neighboring countries, we assumed the prevalence of
HPV infection among the general female population in
Bangladesh would be close to 8%. We utilized the fol-
lowing formula to calculate the sample size [22]:
n ¼ Z
2P 1−Pð Þ
d2
Here n = sample size, Z = Z statistic for a level of confi-
dence, P = expected prevalence or proportion and d =
precision. Using this formula, we calculated the neces-
sary sample size for the urban and rural sites separately
to account for potential differences in loss to follow-up.
For both sites we used the following parameters to
complete our estimates: 8% prevalence, 2% allowable
error, and 95% confidence intervals. For the rural site,
we estimated our loss to follow-up may reach 20%, in-
cluding drop out due to pregnancy during the two-year
follow-up period leading to a target sample size of 883.
For the urban site, we assumed loss to follow-up may
reach 30%, as residents of urban areas are more mobile
than rural areas. Based on this assumption, the target
sample size for the urban site was 1009 women.
Data analysis
Descriptive analyses were conducted to assess demo-
graphic characteristics of participants, by rural and
urban area of residence. Frequency distributions were
presented on background characteristics, including age,
marital status, education, occupation, parity, and
monthly household expenditure as a proxy measure for
socioeconomic status. Test of significance was per-
formed using Chi-square test at 5% level of significance.
Multivariable logistic regression models were generated
separately for urban and rural women to assess factors
associated with “Ever heard of Cervical cancer” and
“Ever heard of HPV vaccine” as dependent variables. Ad-
justed odds ratios (aORs) and its 95% confidence
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intervals (CIs) were estimated. Variables of interest to in-
clude in the multivariable model were initially identified
using the existing literature [23, 24]. Next, these vari-
ables were assessed using univariate analyses. Any factor
that provided a univariate p-value <0.05 for either the
rural or urban model was included in the final multivari-
able regression models. The following variables were ad-
justed for in the models: age, education, occupation, age
at marriage, husband’s education, parity, socioeconomic
status, oral pill use, abortion history, and condom use.
Collinearity was assessed using the variance inflation fac-
tor (VIF) to ensure a strong linear relationship among
independent variables included in the model was not
present. Due to the sampling design and possible effect
modification, data analyses were carried out separately
for urban and rural samples. All statistical analyses were
performed using STATA/SE 12.0.
Results
A total of 3354 eligible women were approached; 1855
in the urban area and 1499 in the rural area. Of the
1855 urban women approached, 1152 (62%) agreed to
participate. Among those who agreed to participate,
1113 (97%) completed interviews. In the rural areas,
1159 of 1499 (77%) eligible women agreed to participate
and 924 (80%) completed interviews. Common reasons
included refused to take part in the study (n = 597; 18%),
failure to attend scheduled interview located at project
office (n = 330; 10%) or were found ineligible based on
study exclusion criteria (pregnant, post-partum, or with
a history of hysterectomy, cervical cancer, uterine pro-
lapse or with major psychological/psychiatric) after
examination conducted by the study physician at enroll-
ment (n = 390; 12%).
Background characteristics
Table 1 presents socio-demographic characteristics of
our study population in urban and rural areas in this
study. Urban and rural women differed significantly on
most socio-demographic characters except parity. In
both urban and rural sites, the average age of women
was 33 years. Significantly more women in the rural area
reported they were married than their urban counterpart
(98% versus 90%; p < 0.001). Overall, women from the
urban site were more educated, with an average of ap-
proximately 7 years of education compared to 5 years of
education among rural women. 16% of urban women re-
ported to work as a garment worker or housemaid com-
pared to about 1% of rural women. Additionally, a
higher proportion of urban women (31%) reported a
monthly expenditure of 20,000 BDT or greater com-
pared to rural women (7%). One-third of rural women
were married at 14 years of age or younger. Urban
women reported to have more educated husbands than
rural women with an average of approximately 9 years’
education compared to about 6 years respectively (p <
0.001). In our sample, significantly more women in rural
areas heard of cervical cancer compared to urban
women (93% versus 90%, p = 0.003). Very few women re-
ported to have ever had a cervical cancer screening test.
There were significantly more women in the urban area
who underwent cervical cancer screening compared to
their rural counterpart (3% versus 1%, p < 0.001). None
of the women in this study reported to have previously
received the HPV vaccine, based on self-report.
Knowledge of cervical cancer and willingness to receive
HPV vaccine
Of the women who reported to have heard of cervical
cancer (n = 1861), only one in ten reported knowing dif-
ferent ways of getting the disease (n = 182) (Table 2).
Urban women reported the most common way of devel-
oping cervical cancer was sexual intercourse (33%),
which in rural women was “poor hygiene during men-
struation” (22%). “Sexual relationship other than hus-
band” was the next common way of getting cervical
cancer in both rural (20%) and urban (21%) women.
Very few women (urban: 6%, rural: 3%) indicated, “not
using a condom” as a way to develop cervical cancer.
Women’s knowledge about prevention of cervical can-
cer was also very poor. Very few women believed that
cervical cancer can be prevented (urban: 7%, rural: 4%).
When asked about the ways this disease can be pre-
vented, the majority thought that cleanliness (urban:
31%, rural: 44%) and maintaining a monogamous sexual
relationship with their husband (urban: 32%, rural: 20%)
was the most effective preventive measure. Over one-
third of rural women mentioned medications as a
method to prevent cervical cancer. 16% of urban women
mentioned vaccination as a preventive method against
cervical cancer compared to 5% of rural women. Very
few women, both in urban and rural areas, were able to
indicate “regular examination by doctor” as a method to
prevent cervical cancer (Table 2). Of the 1861 women
(91%) who reported to have heard of cervical cancer, the
majority of women heard about it from neighbors
(urban: 55%, rural: 66%), relatives (urban: 31%, rural:
45%) and television (urban: 30%, rural: 15%) (Table 2).
Table 3 presents results from the multivariable logistic
regression models of factors associated with having
heard of cervical cancer. After controlling the effects of
other factors in the models, we identified an effect of
age among both urban and rural samples. Among urban
women, the odds of having heard of cervical cancer were
highest among those aged 35–44 years when compared
to those aged less than 24 years (aOR: 2.92, CI: 1.34–
6.33, p = 0.007). In rural women, the odds of having
heard of cervical cancer were significant only for the age
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Table 1 Demographic characteristics of study population to assess knowledge of cervical cancer and the Human Papillomavirus
(HPV) vaccine among ever-married Bangladeshi women (n = 2037)
Urban (n = 1113) Rural (n = 924)
Characteristics n % n % P-Valuea
Age (in years) 0.001
< 24 242 21.7 195 21.2
25–34 432 38.8 328 35.5
35–44 246 22.1 275 29.8
45–64 193 17.3 126 13.6
Mean Age ± SD 33.1 ± 10.3 33.1 ± 8.9
Marital Status <0.001
Married 997 89.6 905 97.9
Separated/Divorced/ Widowed 116 10.4 19 2.1
Religion <0.001
Muslim 1098 98.7 796 86.1
Non-Muslim 15 1.4 128 13.6
Education <0.001
No education 212 19.1 272 29.4
Primary 270 24.3 244 26.4
Secondary or more 631 56.7 408 44.2
Mean Education ± SD 6.7 ± 4.6 4.9 ± 3.9
Occupation <0.001
Housewife 769 69.1 860 93.1
Garments worker / Housemaid 176 15.8 6 0.7
Other workb 168 15.1 58 6.3
Socioeconomic Statusc <0.001
Low (<10,000) 248 22.3 542 58.7
Medium (10,000–19,999) 526 47.3 320 34.6
High (20,000+) 339 30.5 62 6.7
Age at Marriage (in years) <0.001
< = 14 282 25.3 313 33.9
15–19 579 52 515 55.7
20 or more 252 22.6 96 10.4
Mean Age at Marriage ± SD 17.1 ± 3.4 16.0 ± 2.8
Husband’s Education <0.001
No Education 125 11.2 294 31.8
Primary 157 14.1 206 22.3
Secondary or more 831 74.7 424 45.9
Mean Education ± SD 8.9 ± 4.8 5.5 ± 4.5
Parity 0.612
0 76 6.8 63 6.8
1–2 451 40.5 394 42.6
3 + 586 52.7 467 50.5
Mean Parity ± SD 2.9 ± 2.1 2.7 ± 1.7
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group 25–34 years when compared to those aged less
than 24 years (aOR: 2.90, CI: 1.24–6.73, p = 0.014).
Education was identified as a significant factor among
urban women. Urban women with primary education
(aOR: 2.44, CI: 1.33–4.49, p = 0.004) and secondary edu-
cation or above (aOR: 3.76, CI: 1.97–7.18, p < 0.001) had
increased odds of hearing of cervical cancer when com-
pared to urban women with no education. No significant
effect of education was observed among rural women.
Parity was found to be associated with having heard of
cervical cancer for urban women only. In particular, the
odds of having heard of cervical cancer among urban
women with three children or more was 5 times that of
urban women with no children (aOR: 5.28, CI: 2.12–
13.15, p = <0.001). Similarly, socioeconomic status was
only associated with the having heard of cervical cancer
among urban women. The odds of the outcome among
urban women with a high socioeconomic status (SES) was
3.0 times that of the odds of urban women with a low SES
(aOR: 3.00, CI: 1.42–6.34, p = 0.004). And finally, ever
condom usage among urban women was a significant fac-
tor associated with having heard of cervical cancer; the
odds of having heard of cervical cancer was 67% higher
among urban women who reported to have ever used a
condom when compared to those who did not.
Attitude towards HPV vaccination
Twenty-one percent of urban women and only 3% of
rural women reported to have heard of a vaccine that
can prevent cervical cancer (Fig. 1). When asked if they
would take a vaccine to prevent cervical cancer, almost
all women said yes (urban: 94%, rural: 99%). The major-
ity of women were also willing to recommend the vac-
cine to others (urban: 92%, rural: 99%). Participants who
had a daughter were asked if they would be willing to
provide such a vaccine to their daughters to which most
women said yes (urban: 92%, rural: 99%) (Fig. 1).
Table 4 presents results of the multivariable logistic re-
gression models to identify factors associated with hav-
ing heard of the HPV vaccine. Overall, no association
was identified with age after adjusting for covariates pre-
viously identified to be associated with the outcome
among both urban and rural women. Education was as-
sociated with the outcome among urban women only;
the odds of having heard of HPV vaccine among urban
women with secondary education or above was 3.48
times the odds of those with no formal education (aOR:
3.48, 95% CI: 1.67–7.25, p = 0.001). Similarly, age at mar-
riage was only associated with the outcome among
urban women only. Among those married at both 15–
19 years (aOR: 2.18, 95% CI: 1.32–3.60, p = 0.002) and
Table 1 Demographic characteristics of study population to assess knowledge of cervical cancer and the Human Papillomavirus
(HPV) vaccine among ever-married Bangladeshi women (n = 2037) (Continued)
Urban (n = 1113) Rural (n = 924)
Characteristics n % n % P-Valuea
Oral Pill Usage
Ever 874 78.5 799 86.5 <0.001
Never 239 21.5 125 13.5
Abortion History
Ever 417 37.5 91 9.9 <0.001
Never 696 62.5 833 90.2
Tobacco Use
Ever 292 73.8 235 74.5 0.681
Never 821 26.2 689 25.4
Condom Use
Ever 574 51.6 301 32.6 <0.001
Never 539 48.4 623 67.4
Ever Heard of Cervical Cancer 0.003
Yes 998 89.7 863 93.4
No 115 10.3 61 6.6
Ever Underwent Cervical Cancer Screening <0.001
Yes 34 3.1 6 0.7
No 1079 96.9 918 99.4
aCalculated using chi-squared test
bIncludes government and private service, business, daily wager, agriculture, tailor, poultry, handicrafts and tutor
cMonthly Expenditure BDT, 1US$ = 78 BDT
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20 years or above (aOR: 2.83, 95% CI: 1.61–5.00, p <
0.001), the odds were more than doubled when com-
pared to those married at 14 years or below. Finally, high
socioeconomic status was associated with having heard
of HPV vaccine among urban women as well (aOR: 2.25,
95% CI: 1.28–3.95, p = 0.005).
Discussion
In Bangladesh, cervical cancer remains the second most
common cancer among women despite global advances
in its prevention and treatment. Knowledge of cervical
cancer and primary prevention through vaccination is
low, indicating a major public health concern for the na-
tion. Our study found that while a large majority of par-
ticipants (~90%) were aware of cervical cancer, less than
10% had in-depth knowledge of the causes of cervical
cancer and potential preventive measures in place. Add-
itionally, participants reported very limited knowledge of
the HPV vaccine, particularly rural women. This is the
first population-based study conducted in Bangladesh to
demonstrate widespread acceptance of HPV vaccination
among ever-married adult Bangladeshi women, for both
themselves and for their daughters.
To our knowledge, only one other study, the Bangladesh
Midlife Women’s Health Study (BMWHS) has been previ-
ously conducted in Bangladesh to assess women’s know-
ledge of cervical cancer [21]. However, the focus of the
BMWHS’s research question was on cervical cancer
screening and there was no assessment of awareness or
acceptability of HPV vaccination presented. Eighty-one
percent of the study population of BMWHS reported to
have ever heard of cervical cancer, which is lower than
both our rural (90%) and urban population’s (93%) aware-
ness. The investigators of this study did not delve further
into knowledge of cervical cancer and limited their assess-
ment to five questions which focused on cervical cancer
screening. In contrast to our study, the investigators re-
ported that 8.3% of their study population had previously
undergone cervical cancer screening. This is particularly
interesting as the majority (73%) of their study sample was
from rural areas of Bangladesh. In our study, only 3.1% of
urban and 0.7% of rural women reported to have ever
undergone cervical cancer screening. Findings from our
analysis regarding screening rates are comparable to other
surveys conducted in developing countries, particularly
the South-Asian subcontinent [25].
The results of our cross-sectional study are consistent
with other assessments of knowledge and acceptability of
HPV vaccine knowledge conducted in low- and middle-
income countries. Previous studies have reported both
low levels of cervical cancer knowledge and high willing-
ness to receive the HPV vaccine to prevent the develop-
ment of cervical cancer from HPV [19, 26–31]. For
example, in Nepal, previous reports have indicated that
overall about half of women were aware of cervical cancer,
with a higher awareness among urban Nepali women [19].
In-depth knowledge of cervical cancer was low, however,
willingness to have their children vaccinated against HPV
was high. In India, levels of knowledge of cervical cancer
and acceptance of the HPV vaccine vary vastly by region
[32]. In southern India, previous reports have shown that
about one-third of women have heard of HPV while only
15% have heard of cervical cancer [33]. Additionally, only
46 % of women were accepting of vaccination. Research
Table 2 Knowledge of ever-married Bangladeshi women of main
risk factors and prevention measures associated with cervical cancer
(n= 1861) a
Urban Rural
n % n %
Ways to Develop Cervical Cancer (n = 182) b
Sexual Intercourse 33 32.7 11 13.6
Sexual relationship with other than husband 21 20.8 16 19.8
Poor hygiene during Menstruation 18 17.8 18 22.2
General poor hygiene 6 6.0 8 10.0
Husband has a disease 5 4.9 4 4.9
Food / Water 1 0.9 3 3.7
Not using a condom 6 5.9 2 2.5
Skin-to-skin contact 3 2.9 9 11.1
Preventive Methods against Cervical Cancer (n = 121) c
Sexual relationship only with husband 23 32.4 8 19.5
Cleanliness 22 30.9 18 43.9
Vaccination 11 15.5 2 4.9
One-time examination by Doctor 10 14.1 5 12.2
Condom Use 9 12.7 3 7.3
Regular Examination by doctor 3 4.2 0 0.0
Medications 2 2.8 13 31.7
Eating Well 1 1.4 0 0.0
Source of Knowledge of Cervical Cancer
Neighbors 549 55.0 572 66.3
Relatives (besides husband) 304 30.5 389 45.1
Television 301 30.2 127 14.7
Doctor 123 12.3 66 7.7
Other Health Professional 126 12.6 66 7.7
News paper 45 4.5 4 0.5
Colleagues 29 2.9 5 0.6
Radio 12 1.2 5 0.6
Friends 13 1.3 1 0.1
Husband 3 0.3 8 0.9
aPercent may exceed 100% as multiple answers are possible and sample is
limited to those who reported to have heard of cervical cancer
bSample is limited to those who reported to know how a woman can get
cervical cancer (n = 182)
cSample is limited to those who reported to know about preventive methods
for cervical cancer (n = 121)
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Table 3 Factors associated with having heard of cervical cancer among ever-married Bangladeshi women (n = 2037)
Urban Population (n = 1113) Rural Population (n = 918)
Crude ORa P Adjusted ORb P Crude ORa P Adjusted ORb P
Age (in years)
< 24 Ref. Ref. Ref.
25–34 4.09 (2.52–6.61) <0.001 2.73 (1.54–4.82) 0.001 2.84 (1.34–5.99) 0.006 2.90 (1.24–6.73) 0.014
35–44 4.23 (2.35–7.62) <0.001 2.92 (1.34–6.33) 0.007 1.45 (0.75–2.82) 0.269 1.87 (0.72–4.84) 0.198
45–64 3.49 (1.90–6.40) <0.001 2.55 (1.06–6.12) 0.036 1.13 (0.52–2.46) 0.761 1.72 (0.56–5.32) 0.345
Education
No education Ref. Ref. Ref. Ref.
Primary 3.12 (1.77–5.52) <0.001 2.44 (1.33–4.49) 0.004 1.88 (0.93–3.80) 0.079 1.59 (0.75–3.35) 0.228
Secondary or more 6.57 (3.81–11.33) <0.001 3.76 (1.97–7.18) <0.001 3.52 (1.66–7.45) 0.001 2.18 (0.91–5.22) 0.080
Occupation
Housewife Ref. Ref. Ref. Ref.
Garments worker / Housemaid 0.38 (0.24–0.60) <0.001 0.86 (0.52–1.45) 0.588 – – ns
Other workc 0.92 (0.49–1.74) 0.804 0.92 (0.47–1.80) 0.814 3.59 (0.48–26.62) 0.211 3.02 (0.40–22.97) 0.286
Age at Marriage (in years)
≤ 14 Ref. Ref. Ref. Ref.
15–19 0.94 (0.58–1.54) 0.818 0.78 (0.46–1.34) 0.514 1.24 (0.71–2.16) 0.446 0.89 (0.49–1.61) 0.701
≥ 20 1.96 (0.97–3.97) 0.06 1.40 (0.65–3.05) 0.388 2.42 (0.71–8.27) 0.158 1.58 (0.45–5.63) 0.477
Husband’s Education
No Education Ref. Ref. Ref. Ref.
Primary 1.36 (0.72–2.58) 0.349 0.98 (0.49–1.94) 0.954 1.26 (0.66–2.42) 0.488 1.03 (0.52–2.05) 0.927
Secondary or more 3.88 (2.22–6.77) <0.001 1.67 (0.88 - 3.19) 0.115 2.96 (1.52–5.75) 0.001 1.89 (0.88–4.08) 0.104
Parity
0 Ref. Ref. Ref. Ref.
1–2 1.48 (0.80–2.73) 0.210 1.98 (0.99–3.94) 0.051 1.17 (0.45–3.05) 0.747 1.22 (0.46–3.28) 0.680
3 + 2.68 (1.27–5.64) 0.01 5.28 (2.12–13.15) <0.001 1.48 (0.48–4.55) 0.496 1.70 (0.53–5.47) 0.370
Socioeconomic Statusd
Low (<10,000) Ref. Ref. Ref. Ref.
Medium (10,000–19,999) 2.31 (1.50–3.57) <0.001 1.51 (0.94–2.42) 0.086 1.49 (0.83–2.67) 0.183 1.20 (0.66–2.20) 0.541
High (20,000+) 6.43 (3.22–12.82) <0.001 3.00 (1.42–6.34) 0.004 2.62 (0.62–11.15) 0.192 1.28 (0.28–5.78) 0.748
Oral Pill Usage
Never Ref. Ref. Ref. Ref.
Ever 0.93 (0.57–1.52) <0.001 0.89 (0.46–1.37) 0.408 1.81 (0.93–3.52) 0.082 1.40 (0.68–2.84) 0.359
Abortion History
Never Ref. Ref. Ref. Ref.
Ever 0.88 (0.58–1.34) 0.552 0.61 (0.38–1.00) 0.051 2.20 (0.66–7.32) 0.197 1.44 (0.41–4.97) 0.567
Condom Usage
Never Ref. Ref. Ref.
Ever 2.42 (1.55–3.76) <0.001 1.66 (1.03–2.67) 0.036 2.17 (1.12–4.19) 0.021 1.53 (0.77–3.05) 0.229
aAdjusted for age
bAdjusted for age, education, occupation, age at marriage, parity, oral pill usage, abortion history, socioeconomic status (income), condom use,
husband’s education
cIncludes government and private service, business, daily wager, agriculture, tailor, poultry, handicrafts and tutor
dMonthly Expenditure BDT, 1US$ = 78 BDT
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conducted in northern Indian among young school-
attending girls (12–22 years of age) depicts low awareness
(15%) of HPV and cervical cancer, and low acceptance
(13%) of the HPV vaccination [34]. Although cervical can-
cer is the second-leading cause of cancer deaths among
women in India [6] and the HPV vaccine is available in
the Indian market, uptake is low due to low awareness
and knowledge. Efforts should be made in Bangladesh to
avoid a similar scenario and resources should be allocated
to a wide-spread and culturally sensitive educational cam-
paign to market the HPV vaccine as a vaccine against can-
cer for maximum uptake.
The results of our study provide important insight into
sources of knowledge commonly utilized by Bangladeshi
women to obtain information related to health, specifically
cervical cancer and the HPV vaccine. The majority of both
urban and rural participants reported to have heard of cer-
vical cancer from neighbors, family members, and televi-
sion programs. Future preventive programming can utilize
television as a media source to reach a broader audience
[35]. Data from this study also showed the minimal impact
health professionals have on the population in terms of cer-
vical cancer education: Only 12% of urban and 8% women
reported to have heard of cervical cancer from a physician.
Efforts should be made to coordinate all stakeholders, in-
cluding physicians and other health professionals, in the
implementation of successful HPV vaccine programs. Fu-
ture research should assess levels of knowledge of cervical
cancer and its preventative services among health care pro-
viders. This is of particular significance as previous litera-
ture shows health professionals play a key role in vaccine
uptake and that physician recommendation is the strongest
predictor of HPV vaccine uptake among adolescents [36].
A limited number of participants were able to identify
different risk factors of cervical cancer. Participants who
did provide a response for this question most frequently
chose unhygienic menstrual practices, sexual intercourse,
and a sexual relationship with someone other than their
husband as potential ways to develop cervical cancer. Low
condom use was not often chosen, indicating that the
population is not aware of the etiology of HPV and cervical
cancer. This may limit future HPV vaccine programming,
as the population may not recognize the association be-
tween sexually transmitted infections (STIs) and cervical
cancer, and opt out of receiving the vaccination. However,
previous literature has also indicated that the association
between STIs and cervical cancer has hindered efforts to
promote the HPV vaccine in the population [37]. In several
countries, a frequently identified barrier to HPV vaccin-
ation has been parental fears that the vaccine may lead to
sexual promiscuity [38]. This is a vital concern and practi-
tioners involved in primary care, school-based health ser-
vices, and adolescent health should be engaged to avoid
the potential spread of misinformation regarding the safety
and efficacy of the vaccine. Future implementation efforts
should include culturally appropriate educational interven-
tions through the media, particularly the television, in
order to better inform the population of the association be-
tween HPV and cervical cancer.
Similarly, only a small proportion of participants were
able to provide responses regarding preventive methods
against cervical cancer. The majority of participants chose
medications, one-time examination by doctor, cleanliness,
and maintaining a monogamous sexual relationship with
their husband. Only a limited number of the respondents
were able to correctly choose vaccination and regular exam-
ination by a physician. This finding further underscores the
need for widespread educational interventions on cervical
cancer and associated factors, such as risk behaviors and
preventive methods. Such educational interventions can be
targeted to groups who were identified to be less likely to
have heard of cervical cancer based on multivariable ana-
lyses. These groups include: younger women in urban and
rural areas, women with either no or low education in
urban areas and rural areas, urban women with low income,
and urban women who do not use condoms.
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Fig. 1 Willingness to vaccinate against cervical cancer among ever-married Bangladesh women (n = 1861)
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Table 4 Factors associated with having heard of HPV Vaccine among ever-married Bangladeshi women (n = 2037)
Urban Population (n = 1113) Rural Population (n = 918)
Crude ORa P Adjusted ORb P Crude ORa P Adjusted ORb P
Age (in years)
< 24 Ref. Ref. Ref. Ref.
25–34 1.54 (1.01–2.36) 0.042 1.13 (0.68–1.89) 0.632 1.57 (0.55–4.47) 0.4 1.30 (0.39–4.36) 0.674
35–44 1.25 (0.77–2.01) 0.37 0.93 (0.50–1.73) 0.548 0.99 (0.31–3.17) 0.99 0.88 (0.20–3.90) 0.869
45–64 1.54 (0.94–2.53) 0.085 1.49 (0.75–2.95) 0.329 1.57 (0.45–5.53) 0.483 1.54 (0.29–8.13) 0.612
Education
No education Ref. Ref. Ref. Ref.
Primary 1.89 (1.02–3.47) 0.042 1.87 (0.88–4.00) 0.104 2.22 (0.70–7.01) 0.175 2.20 (0.65–7.41) 0.204
Secondary or more 4.37 (2.56–7.48) <0.001 3.48 (1.67–7.25) 0.001 2.63 (0.86–8.03) 0.09 2.28 (0.62–8.33) 0.213
Occupation
Housewife Ref. Ref. Ref. Ref.
Garments worker / Housemaid 0.42 (0.24–0.71) 0.001 0.82 (0.43–1.58) 0.559 – –
Other workc 0.93 (0.62–1.41) 0.748 0.98 (0.62–1.54) 0.93 2.32 (0.77–7.02) 0.135 2.31 (0.71–7.48) 0.162
Age at Marriage (in years)
≤ 14 Ref. Ref. Ref. Ref.
15–19 2.09 (1.36–3.21) 0.001 2.18 (1.32–3.60) 0.002 1.14 (0.50–2.63) 0.754 1.11 (0.44–2.78) 0.823
≥ 20 3.02 (1.88–4.84) <0.001 2.83 (1.61–5.00) <0.001 1.45 (0.43–4.89) 0.546 1.24 (0.32–4.73) 0.756
Husband’s Education
No Education Ref. Ref. Ref. Ref.
Primary 1.13 (0.55–2.32) 0.743 0.53 (0.22–1.26) 0.149 2.52 (0.80–7.94) 0.114 2.80 (0.84–9.30) 0.092
Secondary or more 2.07 (1.17–3.67) 0.013 0.69 (0.34–1.42) 0.314 2.54 (0.91–7.10) 0.075 2.42 (0.76–7.71) 0.134
Parity
0 Ref. Ref. Ref. Ref.
1–2 0.86 (0.45–1.64) 0.654 0.90 (0.44–1.82) 0.768 0.81 (0.17–3.94) 0.794 0.90 (0.18–4.47) 0.899
3 + 0.92 (0.47–1.80) 0.797 1.50 (0.66–3.37) 0.331 1.15 (0.21–6.30) 0.875 1.57 (0.27–9.15) 0.614
Socioeconomic Statusd
Low (<10,000) Ref. Ref. Ref. Ref.
Medium (10,000–19,999) 1.49 (0.93–2.39) 0.095 1.20 (0.70–2.03) 0.511 0.55 (0.23–1.30) 0.176 0.49 (0.20–1.20) 0.119
High (20,000+) 3.62 (2.25–5.82) <0.001 2.25 (1.28–3.95) 0.005 0.83 (0.19–3.65) 0.809 0.63 (0.14–2.92) 0.554
Oral Pill Usage
Never Ref. Ref. Ref. Ref.
Ever 0.96 (0.66–1.38) 0.819 1.02 (0.67–1.55) 0.93 0.51 (0.21–1.23) 0.135 0.43 (0.17–1.01) 0.079
Abortion History
Never Ref. Ref. Ref. Ref.
Ever 0.95 (0.70–1.30) 0.823 0.84 (0.57–1.23) 0.363 1.46 (0.48–4.40) 0.503 1.17 (0.36–3.80) 0.799
Condom Usage
Never Ref. Ref. Ref. Ref.
Ever 1.54 (1.10–2.15) 0.012 1.13 (0.79–1.62) 0.515 0.87 (0.39–1.95) 0.741 0.74 (0.31–1.76) 0.498
aAdjusted for age
bAdjusted for age, education, occupation, age at marriage, parity, oral pill usage, abortion history, socioeconomic status (income), condom use,
husband’s education
cIncludes government and private service, business, daily wager, agriculture, tailor, poultry, handicrafts and tutor
dMonthly Expenditure BDT, 1US$ = 78 BDT
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Although findings from this study are novel and timely
for successful HPV vaccine program implementation, sev-
eral limitations should be taken into consideration when
interpreting these results. Participants included in this
study resided in surveillance sites of icddr,b. where they
have frequently participated in various public health initia-
tives and research projects. This frequent exposure to
public health programming may explain the population’s
widespread willingness to receive the HPV vaccination or
a vaccine to prevent cervical cancer. As such, this sample
may not be representative of the entire population, how-
ever, one can expect even lower knowledge in the broader
population outside of the surveillance site. Additionally,
questions included in this survey were close-ended; open-
ended questions may have provided the opportunity to
better assess cervical cancer and HPV related knowledge,
perceived risk and awareness, especially when no prior
data were available for this population.
The high level of willingness to receive a vaccine to pre-
vent cervical cancer despite low knowledge of cervical
cancer presents potential ethical issues and underscores
the need to provide educational programs. This will en-
sure that Bangladeshi women are able to make informed
decisions on their health and that of their families. Add-
itionally, in the absence of accessible regular screening
programs, the implementation of an HPV immunization
program should be a public health priority in Bangladesh.
In our study population, only 1.9% of the entire sample
had previously undergone screening for cervical cancer.
This finding is consistent with previous literature pub-
lished in 2012, which estimated that only 1.1% of the
women in Bangladesh had previously undergone cervical
cancer screening based on data collected in 2003 [25].
Based on these results, it is reasonable to conclude that
rates of cervical cancer screening have not improved over
the last decade in Bangladesh. Previous studies have
shown that low awareness and socioeconomic barriers can
potentially lead to underutilization of screening services
for women. Education of women by healthcare workers is
an important factor for increasing screening rates [39]. Fu-
ture research is needed to explore the level of knowledge
of cervical cancer in other populations at high risk.
Conclusions
This study provides the first population-based assessment
of willingness to receive the HPV vaccine. These findings
are timely as the Government of Bangladesh has recently
obtained support from GAVI to provide a national HPV
vaccine program to school-aged adolescent girls. The find-
ings from this study provide the necessary country-
specific evidence for the development of this program.
Despite high levels of awareness of cervical cancer, in-
depth knowledge of causes of cervical cancer and how it
can be prevented is low. Additionally, cervical cancer
screening was very low in this population. These findings
underscore the necessity for culturally appropriate and
targeted educational interventions to improve knowledge
of cervical cancer causes and its primary prevention
through the HPV vaccine. Despite low knowledge about
the disease and its prevention, there was a high level of
willingness to receive a vaccine to prevent cervical cancer.
As such, this survey suggests that the HPV vaccine would
likely be an accepted addition to routine vaccinations in
Bangladesh. Findings from this study have important im-
plications for designing and implementing HPV vaccine
programs, and educational efforts in the country.
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